Thirty Years of Waiting: Why Finerenone’s FDA Approval Exposes a Systemic Gap in Diabetic Kidney Disease Innovation

On December 20, 2023, the U.S. Food and Drug Administration approved finerenone for chronic kidney disease in adults with type 1 diabetes. To the clinician managing a young patient with progressive albuminuria, the news felt overdue—not as a recent breakthrough, but as a correction of a deficit that should never have existed.

Three decades without a new therapeutic class for a major diabetic complication is not a minor regulatory gap. It is a window into how health systems prioritize innovation, tolerate clinical inertia, and allocate research capital when facing chronic diseases that affect millions globally. The approval of finerenone—a selective nonsteroidal mineralocorticoid receptor antagonist—is scientifically important. But the delay in its arrival raises questions more profound than any single trial outcome.

Type 1 diabetes affects approximately 1.5 million Americans and 8 million people worldwide. Diabetic kidney disease remains the leading cause of end-stage renal disease in developed nations. Yet between the introduction of angiotensin-converting enzyme inhibitors in the 1980s and finerenone’s approval last year, the therapeutic toolkit for this population barely evolved. Intensified glycemic control improved outcomes marginally. Renin-angiotensin system blockade offered renoprotection but incomplete prevention of decline. Beyond those interventions, clinicians faced a therapeutic plateau that persisted through two generations of practice.

Why did this void exist?

The answer implicates multiple systems simultaneously. First, type 1 diabetes has historically occupied less commercial attention than type 2, despite its greater individual disease burden and earlier age of onset. The market incentive to develop novel agents tilted toward the larger population of type 2 diabetics, even though the pathophysiology of type 1 diabetic kidney disease—absolutely insulin-dependent, autoimmune in origin—represents a fundamentally different problem demanding distinct therapeutic approaches.

Second, regulatory pathways favored surrogate endpoints—albuminuria reduction—over hard clinical outcomes until recently. Early-stage trials showed promise for mineralocorticoid antagonism, but translating that signal into an approvable indication required decades of patient follow-up and outcome accrual. This is not inherently wrong; rigorous evidence demands time. Yet the cumulative effect was that a generation of patients experienced progressive renal decline while regulatory science moved methodically toward proof.

Third, clinical guideline committees moved cautiously. Mineralocorticoid receptor antagonists had entered the nephrologic consciousness primarily in the context of resistant hypertension and hyperkalemia risk. The leap to their incorporation as disease-modifying therapy in type 1 diabetic kidney disease required not merely new data but a shift in how specialists conceptualized the condition itself. Institutional inertia is real; it is not negligence, but it is costly.

The finerenone trials—FIGARO-DKD and FIDELITY—demonstrated a 18% to 25% relative risk reduction in progression to end-stage renal disease or doubling of serum creatinine over four years. These are meaningful reductions. Combined with SGLT2 inhibitor therapy, which entered this space more recently, finerenone offers additive benefit through a mechanistically complementary pathway. The clinical result is that a patient presenting today with type 1 diabetes and early chronic kidney disease has access to a more sophisticated multitarget approach than was available to similar patients five years ago.

But the innovation timeline—from initial mechanistic observation to regulatory approval spanning decades—merits institutional reflection. It raises uncomfortable questions: Do our research funding mechanisms adequately support investigation of therapeutic gaps in smaller populations? Do regulatory expectations, while appropriately demanding rigorous evidence, inadvertently penalize innovation in indications with smaller enrolled populations or longer follow-up requirements? Do our clinical networks update guidelines as rapidly as emerging evidence warrants?

For the Georgian health system, as for systems worldwide, finerenone’s approval signals opportunity and obligation simultaneously. Opportunity because type 1 diabetic kidney disease respects no geography, and Georgian patients deserve access to contemporary therapeutic options. Obligation because integrating finerenone into clinical practice, establishing reimbursement pathways, and training clinicians to recognize which patients will benefit requires deliberate effort across payers, educators, and providers.

The approval of finerenone should not be celebrated as innovation finally catching up to need; it should be examined as evidence that our systems tolerated a 30-year delay in therapeutic advance for a serious, progressive condition affecting millions. The question now is whether we apply that lesson to the next therapeutic gap—or allow another generation to wait.